8-K: Tyra Biosciences Reports Promising Dabogratinib Phase 2 Data

Tyra Biosciences announced initial positive results from its Phase 2 SURF302 study of dabogratinib for bladder cancer, identifying a potential optimal dose and demonstrating clinical proof of concept.

Summary

• Tyra Biosciences announced initial results from its Phase 2 SURF302 study evaluating oral dabogratinib for Fibroblast Growth Factor Receptor (FGFR) 3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC).
• The study provided clinical proof of concept for selective oral FGFR3 inhibition and identified 60 mg once-daily (QD) as the potential dose for future registrational development.
• Initial safety and tolerability were favorable, with most treatment-emergent adverse events (TEAEs) being Grade 1 or 2. Grade 3 TEAEs occurred in 14% at 60 mg and 9% at 50 mg, with no Grade 4 or 5 TEAEs.
• At the 60 mg QD dose, there were no dose reductions or treatment-related discontinuations, and no clinically significant hyperphosphatemia, nail toxicity, or ocular toxicity was observed.
• Initial efficacy results showed an Overall Response Rate (ORR) of 79% (11/14) for the 60 mg QD cohort and 67% (8/12) for the 50 mg QD cohort at the 3-month assessment.
• Complete Response (CR) rates were 57% (8/14) for 60 mg QD and 33% (4/12) for 50 mg QD.
• The company also reported initial observations from SURF303 in low-grade upper tract urothelial cancer (LG UTUC) and updates on dose level clearance in BEACH301 for achondroplasia.
• Tyra plans to engage health authorities on Phase 3 study design and dose selection, with a registrational adjuvant study expected to initiate in 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with strong initial efficacy and favorable safety data from the SURF302 study, supporting the advancement of dabogratinib.

Positives

• Clinical proof of concept for selective oral FGFR3 inhibition established.
• 60 mg once-daily (QD) identified as the potential dose for registrational development.
• Favorable initial safety and tolerability profile observed across both 60 mg and 50 mg QD cohorts.
• No Grade 4 or 5 treatment-emergent adverse events (TEAEs) reported.
• No dose reductions or treatment-related discontinuations at the 60 mg QD dose.
• Absence of clinically significant hyperphosphatemia, nail toxicity, or ocular toxicity.
• High Overall Response Rates (ORR) observed: 79% for 60 mg QD and 67% for 50 mg QD at 3-month assessment.
• Complete Response (CR) rates of 57% for 60 mg QD and 33% for 50 mg QD at 3-month assessment.

Negatives

• Grade 3 TEAEs occurred in 14% of participants at 60 mg QD and 9% at 50 mg QD.
• Grade 3 treatment-related AEs occurred in 4.5% of participants across both cohorts (both at 50 mg QD).
• Preliminary exposure-response analyses suggest a potential benefit for higher steady-state exposure (AUC threshold of 2500 ng.hr/mL) for ORR (86% vs 58%).
• The company plans to initiate a 70 mg QD cohort to explore dabogratinib in the ablative setting, indicating potential need for higher doses in certain scenarios.

Risks

• Initial or interim results of a clinical trial are not necessarily indicative of final results and may materially change.
• Preliminary pharmacokinetic, pharmacodynamic and exposure-response analyses may not be predictive of future clinical outcomes or later-stage studies.
• Early clinical observations may not be predictive of future results.
• The safety and efficacy observed to date may not continue in ongoing or future studies.
• The timing and outcome of interactions with regulatory authorities regarding Phase 3 study design and dose selection may differ from expectations.
• The potential market opportunity in IR NMIBC and commercial opportunity for dabogratinib may be smaller than estimated.
• Risks and uncertainties described in the company's Annual Report on Form 10-K and subsequent filings with the SEC.

Future Outlook

Tyra Biosciences plans to complete enrollment in the 60 mg QD cohort and initiate a 70 mg QD cohort to explore dabogratinib in the ablative setting. The company intends to engage health authorities on Phase 3 study design and dose selection, with a registrational adjuvant study expected to be initiated in 2027.

Management Comments

• The study provided clinical proof of concept for selective oral FGFR3 inhibition and identified 60 mg once-daily (QD) as the potential dose supporting TYRA's planned registrational adjuvant development strategy.
• TYRA believes these results are consistent with the potential for chronic once-daily administration.
• Based on third-party market research, TYRA estimates a potential total market opportunity for IR NMIBC of greater than $5 billion, assuming full penetration of branded agents across the FGFR3-altered patient population.

Industry Context

StockSavvy.ai notes that the development of targeted therapies for FGFR3-altered cancers, particularly in the non-muscle invasive bladder cancer (NMIBC) space, is a significant area of focus. The market opportunity estimated by Tyra Biosciences, if realized, would indicate a substantial unmet need for effective adjuvant therapies in this patient population.

Comparison to Industry Standards

• The reported Overall Response Rate (ORR) of 79% at 3 months for the 60 mg QD cohort in the SURF302 study is a strong indicator, though direct comparisons to industry standards for this specific patient population (LG IR NMIBC with FGFR3 alterations) are limited due to the novelty of targeted therapies in this niche.
• The absence of Grade 4 or 5 TEAEs and the manageable nature of Grade 3 TEAEs align with industry expectations for well-tolerated oral therapies, especially for chronic administration.
• The estimated market opportunity of over $5 billion for IR NMIBC, assuming full penetration, suggests a significant commercial potential if dabogratinib proves effective and safe in larger registrational trials, comparable to other high-value oncology markets.

Stakeholder Impact

• Shareholders: Positive impact expected due to promising clinical data and advancement towards registrational studies, potentially increasing the company's valuation.
• Patients: Potential for a new, effective oral treatment option for FGFR3-altered LG IR NMIBC, with favorable safety and tolerability.
• Healthcare Providers: Introduction of a targeted therapy that could improve treatment outcomes and reduce recurrence rates in a specific patient subgroup.

Next Steps

• Complete enrollment in the 60 mg QD cohort of SURF302.
• Initiate a 70 mg QD cohort in SURF302 to explore dabogratinib in the ablative setting.
• Engage health authorities on Phase 3 study design and dose selection.
• Continue preparations for a planned registrational adjuvant study expected to be initiated in 2027.

Key Dates

Recommendation

The initial Phase 2 data for dabogratinib is promising, demonstrating proof of concept, favorable safety, and encouraging efficacy. However, the results are preliminary, and the company is still in the early stages of registrational development. Further data from ongoing studies and successful engagement with regulatory authorities are crucial before a more definitive 'buy' recommendation can be made. A 'hold' reflects the positive outlook tempered by the inherent risks and uncertainties of late-stage clinical development.

Keywords

dabogratinib, FGFR3, NMIBC, bladder cancer, urothelial cancer, oncology, clinical trial, drug development